OT 82

Drug Profile

OT 82

Alternative Names: OT-82

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTartis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 11 Dec 2017 OncoTartis plans a phase I trial for Haematological malignancies (Trial profile 700291250)
  • 01 Apr 2017 Preclinical data in Leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 01 Aug 2016 Preclinical trials in Haematological malignancies in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top